Ruthenium and iridium based mononuclear and multinuclear complexes: A Breakthrough of Next-Generation anticancer metallopharmaceuticals
Authors:
- Binoy KarBKBinoy Kar
- Nilmadhab RoyNRNilmadhab Roy
- Sudhindra PeteSPSudhindra Pete
- Prithvi MoharanaPMPrithvi Moharana
- Priyankar PairaPPPriyankar Paira
- 1 November 2020
- journal article
- review article
- Published by Elsevier in Inorganica Chimica Acta
- Vol. 512
Abstract
No abstract availableKeywords
Funding Information
- Department of Science and Technology, Ministry of Science and Technology, India
This publication has 85 references indexed in Scilit:
- Organometallic Half-Sandwich Iridium Anticancer ComplexesJournal of Medicinal Chemistry, 2011
- Organometallic Anticancer CompoundsJournal of Medicinal Chemistry, 2010
- Arsenic in Cancer Treatment: Challenges for Application of Realgar Nanoparticles (A Minireview)Toxins, 2010
- The global burden of cancer: priorities for preventionCarcinogenesis, 2009
- How do real tumors become resistant to cisplatin?Cell Cycle, 2008
- Metal-Based TherapeuticsScience, 2007
- Classical and Non‐Classical Ruthenium‐Based Anticancer Drugs: Towards Targeted Chemotherapy (Eur. J. Inorg. Chem. 20/2006)European Journal of Inorganic Chemistry, 2006
- KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development ? an overviewInt. Journal of Clinical Pharmacology and Therapeutics, 2005
- Bipyrimidine-Bridged Mixed-Metal Trimetallic Complexes of Ruthenium(II) with Rhodium(III) or Iridium(III), {[(bpy)2Ru(bpm)]2MCl2}5+Inorganic Chemistry, 1996
- Arene ruthenium(II) complexes formed by dehydrogenation of cyclohexadienes with ruthenium(III) trichlorideJ. Chem. Soc., Dalton Trans., 1974